Efficacy and Safety of DLBS2411 in the Management of GERD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-16

Study Completion Date

2020-09-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 2-arm, prospective, double-blind double-dummy, randomized-controlled study comparing DLBS2411 at a dose of 250 mg twice daily with omeprazole at a dose of 20 mg twice daily, given before morning and evening meals, for an 8-week course of therapy. Subjects should avoid taking meals 2-3 hours before bedtime.

The bioactive fraction of DLBS2411 has been proved at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its cytoprotective defense mechanism works through the promotion of cyclooxygenase-2 (COX-2) derived prostaglandin (PgE2) synthesis, thus promoting gastrointestinal submucosal blood-flow, stimulating secretion of gastric-epithelial mucous and bicarbonate; anti-oxidative activity; and endothelial-nitric oxide (NO) formation.

Recent study of DLBS2411 which was conducted in healthy volunteers, demonstrated the effective role and safety of DLBS2411 in suppressing intragastric acidity. Having such mechanisms of action, DLBS2411 is hypothesized to benefit patients with gastric acid disorders such as in gastroesophageal reflux disease (GERD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

DLBS2411 Treatment For Functional Dyspepsia

NCT05248802

Functional Dyspepsia

RECRUITING PHASE3

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

NCT01642615

Gastroesophageal Reflux Disease Erosive Esophagitis

COMPLETED PHASE2

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

NCT01642602

Gastroesophageal Reflux Disease

COMPLETED PHASE2

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

NCT00321984

Gastroesophageal Reflux Disease

COMPLETED PHASE3

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

NCT02615184

Erosive Esophagitis

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There will be 2 groups of treatment; each group will consist of 129 subjects with the treatment regimens for 8 weeks:

Treatment I : 1 capsule of Omeprazole 20 mg and 1 placebo caplet of DLBS2411, twice daily Treatment II : 1 caplet of DLBS2411 250 mg and 1 placebo capsule of omeprazole, twice daily

Each study medication will be administered twice daily, 30 minutes before morning (the first) and evening (the last) meals.

The eligible subjects will be randomly allocated to receive study medication (Treatment 1 or Treatment 2) for 8 weeks of treatment, in a double blind fashion. They will be asked to come to the clinic every 4-week interval throughout the study period. Treatment Group 1 will receive Omeprazole twice daily and Placebo DLBS2411 twice daily. While Treatment Group 2 will receive DLBS2411 twice daily and Placebo Omeprazole twice daily.

Subjects will be evaluated for treatment efficacy at baseline and at interval of 4 weeks over the 8-week course of therapy. Throughout the 8-week therapy, subjects should record the frequency (presence and absence) of each of GERD symptoms (heartburn, regurgitation, epigastric pain, nausea) daily in the provided Patient's Diary. The severity of each symptom experienced should also be self-evaluated and recorded.

The safety profile of study medication other than vital signs and adverse event will be measured at baseline and end of study.

Along the study, subjects should avoid taking meals 2-3 hours before bedtime. All subjects will be under direct supervision of a medical doctor during the study period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux Disease (GERD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment 1

1 Omeprazole capsule 20 mg and 1 placebo caplet of DLBS2411, twice daily

Group Type ACTIVE_COMPARATOR

Omeprazole

Intervention Type DRUG

1 Omeprazole 20 mg capsules twice daily

Placebo caplet of DLBS2411

Intervention Type DRUG

1 placebo caplet of DLBS2411, twice daily

Treatment II

1 DLBS2411 caplet 250 mg and 1 placebo capsule of Omeprazole, twice daily

Group Type EXPERIMENTAL

DLBS2411

Intervention Type DRUG

1 DLBS2411 caplet 250 mg, twice daily

Placebo capsule of Omeprazole

Intervention Type DRUG

1 placebo capsule of omeprazole, twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omeprazole

1 Omeprazole 20 mg capsules twice daily

Intervention Type DRUG

DLBS2411

1 DLBS2411 caplet 250 mg, twice daily

Intervention Type DRUG

Placebo capsule of Omeprazole

1 placebo capsule of omeprazole, twice daily

Intervention Type DRUG

Placebo caplet of DLBS2411

1 placebo caplet of DLBS2411, twice daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Redacid Placebo caplet of Redacid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Agree to participate in the study under signed informed consent.
2. Male or female subjects aged 18-65 years old.
3. Subjects with diagnosis of GERD confirmed by endoscopy, with esophagitis grade A-B according to the LA Classification.
4. Able to take oral medication.
5. Subjects or subjects' legally acceptable representatives are able and willing to record adverse events in diary.
6. Subjects or subjects' legally acceptable representatives have the ability to comply with the trial protocol, including instruction for taking trial medication.

Exclusion Criteria

1. For females of childbearing potential: pregnancy and breast-feeding.

* Patients must accept pregnancy tests during the trial if menstrual cycle is missed
* Fertile patients must use a reliable and effective contraceptive
2. Subjects with Zollinger Ellison syndrome or peptic ulcer diseases.
3. History or current evidence of Barrett's esophagus, esophageal strictures, odynophagia, pyloric stenosis, esophageal motility disorders (such as achalasia, scleroderma), anatomic esophageal abnormality (such as large hiatal hernia), pill-induced esophagitis.
4. Helicobacter pylori positive as confirmed by urea breath test (UBT).
5. History of esophageal, gastric or intestinal surgery including vagotomy.
6. Presence of comorbid diseases, such as symptomatic coronary artery disease (CAD) or cardiovascular disease, pulmonary disease (including asthma), hemostasis disorder, pancreatitis, malabsorption, or inflammatory bowel disease, and any other chronic diseases (including chronic cough, laryngitis), any serious infection(s), or malignancy(ies).
7. Inadequate liver function defined as ALT or alkaline phosphatase \> 2.5 times upper limit of normal.
8. Inadequate renal function defined as estimated Glomerular Filtration Rate (eGFR) \< 60 mL/min.
9. Taking any proton pump inhibitors (PPIs) or sucralfate within 14 days prior to screening.
10. Requiring regular and chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids, aspirin, anticholinergics, cholinergics, spasmolytics, or opiates, misoprostol or prokinetics.
11. Hypersensitivity to proton pump inhibitors.
12. Subjects with chronic alcoholism (\>40 g alcohol/day) or drug abuse.
13. Active heavy smokers (i.e. consuming \>10 cigarettes per day).
14. Participation in any other clinical studies within 30 days prior to screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dadang Makmun, SpPD, KGEH

Role: PRINCIPAL_INVESTIGATOR

Division of Gastroenterology Department of Internal Medicine Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo National General Hospital, Jakarta Indonesia

Iswan A. Nusi, Prof. KGEH, FINASIM, FACG

Role: PRINCIPAL_INVESTIGATOR

Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Airlangga Dr. Soetomo Hospital, Surabaya, Indonesia

Putut Bayupurnama, SpPD, KGEH

Role: PRINCIPAL_INVESTIGATOR

Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Gadjah Mada Dr. Sardjito Hospital, Yogyakarta, Indonesia

Hery D. Purnomo, SpPD, KGEH

Role: PRINCIPAL_INVESTIGATOR

Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Diponegoro Dr. Kariadi Hospital, Semarang, Indonesia

Dolvy Girawan, M. Kes., SpPD, KGEH

Role: PRINCIPAL_INVESTIGATOR

Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Padjajaran Dr. Hasan Sadikin Hospital, Bandung, Indonesia